Adjuvant Therapy
Use of Intera 3000 Hepatic Artery Infusion Pump for patients with resected Colorectal Liver Metastases (CLM) (adjuvant therapy):
2,368 patients who underwent complete resection of CLM at Memorial Sloan Kettering were consecutively enrolled in a prospectively maintained database.
- Patients who received the Intera 3000 HAI Pump plus systemic chemotherapy had a median overall survival of 67 months. Patients who received systemic chemotherapy alone had a median survival of 47 months (P<0.001).
- In propensity score analysis, the same strong association with overall survival was found with an adjusted hazard ratio for HAI of 0.67 (P < 0.001).
- Patients who received the Intera 3000 HAI Pump plus systemic chemotherapy had overall survival of 52.9% at 5 years versus overall survival of 37.9% with systemic chemotherapy alone (P<0.001).
- Patients who received the Intera 3000 HAI Pump plus systemic chemotherapy had overall survival of 38.0% at 10 years versus overall survival of 23.8% with systemic chemotherapy alone (P<0.001).
- Use of the Intera 3000 HAI Pump was not associated with increased overall survival in patients with extrahepatic disease, a positive resection margin, or a clinical risk score of 4 or 5. Overall survival for patients in this study who did not receive the Intera 3000 HAI Pump was similar to overall survival in other large studies without the Intera 3000 HAI Pump.
